Attached files
| file | filename |
|---|---|
| EX-31.2 - EXHIBIT 31.2 - Sorrento Tech, Inc. | a201703ex-312.htm |
| EX-31.1 - EXHIBIT 31.1 - Sorrento Tech, Inc. | a201703ex-311.htm |
| EX-10.2 - EXHIBIT 10.2 - Sorrento Tech, Inc. | ex102leaseamendment.htm |
| EX-10.1 - EXHIBIT 10.1 - Sorrento Tech, Inc. | ex101loanamendment.htm |
| EX-4.3 - EXHIBIT 4.3 - Sorrento Tech, Inc. | ex43comericawarrant04062017.htm |
| EX-4.2 - EXHIBIT 4.2 - Sorrento Tech, Inc. | ex421stamendmenttocomerica.htm |
| EX-4.1 - EXHIBIT 4.1 - Sorrento Tech, Inc. | ex412ndamendmenttocomerica.htm |
| 10-Q - 10-Q - Sorrento Tech, Inc. | a331201710-q.htm |
Exhibit 32.1
CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
Each of the undersigned officers of Roka Bioscience, Inc. (the “Company”) hereby certifies to his knowledge that the Company’s Quarterly Report on Form 10-Q for the period ended March 31, 2017 (the “Report”), as filed with the Securities and Exchange Commission on the date hereof, fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, as amended, and that the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
Date: May 12, 2017
/s/ Mary Duseau |
Mary Duseau |
President and Chief Executive Officer |
(Principal Executive Officer) |
Date: May 12, 2017
/s/ Lars Boesgaard |
Lars Boesgaard |
Vice President and Chief Financial Officer |
(Principal Financial and Accounting Officer) |